| ¿µ¹® | white blood cell(WBC), leukocyte | ÇÑ±Û | ¹éÇ÷±¸ |
|---|---|---|---|
| ¼³¸í | Ç÷¾×³»¿¡ °ñ¼ö±¸°è¼¼Æ÷¿Í ¸²ÇÁ°è¼¼Æ÷, ´ÜÇÙ±¸°è¼¼Æ÷¸¦ ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ¹éÇ÷±¸ÀÇ Áõ°¡°¡ ÀÖÀ¸¸é ´ë°³ °¨¿°ÀÌ Àְųª, ȤÀº Å»¼öÇö»óÀÌ ÀÖÀ½À» ÀǹÌÇÑ´Ù. ¶ÇÇÑ Áö³ªÄ£ ¹éÇ÷±¸¼öÀÇ °¨¼Ò´Â ÀÎü³» ¸é¿ª±â´ÉÀÌ ¶³¾îÁ® ÀÖÀ½À» ÀǹÌÇϸç, ´Ù¸¥ Áúº´¿¡ ÀÇÇØ ³ªÅ¸³ª´Â ÀÌÂ÷ÀûÀÎ Çö»óÀÌ ¾Æ´ÑÁö ²À Áø´ÜÀ» ¹Þ¾Æº¸¾Æ¾ß ÇÑ´Ù. |
||
| ¿µ¹® | mast cell | ÇÑ±Û | ºñ¸¸ ¼¼Æ÷ |
|---|---|---|---|
| ¼³¸í | µ¿¹°ÀÇ °áÇÕ Á¶Á÷ °¡¿îµ¥ ³Î¸® ºÐÆ÷ÇÏ´Â ¼¼Æ÷. °áÇÕÁ¶Á÷°ú Á¡¸·Á¶Á÷ ³»¿¡ Àִ ȣ¿°±â¼º »ö¼Ò·Î ÀÌ¿°»ö¼º(metachromasia)À» ³ªÅ¸³»´Â °ú¸³À» °¡Áø ¹æÃßÇüÀÇ ¼¼Æ÷¿¡ ÀÛÀº µÕ±Ù ÇÙÀ» °¡Áø´Ù. ºñ¸¸¼¼Æ÷ÀÇ Ç¥¸é¿¡´Â IgE¿¡ ´ëÇÑ ¼ö¿ëü°¡ Á¸ÀçÇϸç, ¼ö¿ëü¿¡ °áÇÕÇÑ IgE ºÐÀڵ鳢¸® ´Ù°¡ÀÇ Ç׿ø¿¡ ÀÇÇØ ¼·Î ¿¬°áµÇ¸é ºñ¸¸¼¼Æ÷ °ú¸³Å»Ãâ ¹ÝÀÀÀÌ ÀϾ, È÷½ºÅ¸¹Î, ¼¼·ÎÅä´Ñ, ÇìÆÄ¸° µîÀÇ ÈÇÐÀü´Þ ¹°ÁúÀÌ ¹æÃâµÇ¾î, Áï½ÃÇü ¾Ë·¹¸£±â ¹ÝÀÀ µîÀÇ Áõ»óÀ» ÀÏÀ¸Å²´Ù. ÇǺÎ, À帷, Ç÷°ü ÁÖÀ§, Á¡¸· ÁÖº¯¿¡ ÀÖ´Ù. |
||
| ¿µ¹® | cell-mediated immunity | ÇÑ±Û | ¼¼Æ÷¸Å°³¸é¿ª |
|---|---|---|---|
| ¼³¸í | ¸é¿ªÀ̶õ ½Åü¸¦ ¿ÜºÎÀÇ ¹°Áú·ÎºÎÅÍ º¸È£ÇÏ´Â ÇàÀ§¸¦ ¸»ÇÑ´Ù. ¿©±â¿¡´Â ƯÀÌÀû ¸é¿ª°ú ºñƯÀÌÀû ¸é¿ªÀÇ µÎ °¡Áö°¡ ÀÖ´Ù. ºñƯÀÌÀû ¸é¿ªÀ̶óÇÔÀº ƯÁ¤ÇÑ ¹°Áú¿¡ °ü°èÇÏ´Â ¸é¿ªÀÌ ¾Æ´Ï¶ó ƯÁ¤ ´ë»óÀÌ ¾øÀÌ ¸ðµç ¿ÜºÎ ¹°Ã¼¿¡ ÀÛ¿ëÇÒ ¼ö ÀÖ´Â ¸é¿ªÀ» ¸»ÇÑ´Ù. ¿©±â¿¡´Â ¼Òº¯ÀÇ È帧, ´«¹°ÀÇ È帧, ÇǺÎÀÇ ºñÅõ°ú¼º µîÀÇ ±â°èÀûÀÎ °Íµµ Æ÷ÇԵǰí ÇǼӿ¡ µ¹¾Æ´Ù´Ï´Â ¼¼Æ÷ Áß¿¡¼ ºñƯÀÌÀûÀ¸·Î ¿ÜºÎÀÇ ¹°ÁúÀ» Æ÷½ÄÇÏ´Â ¼¼Æ÷µé(¿¹¸¦ µé¸é Å«Æ÷½Ä¼¼Æ÷(macrophage)ÀÇ È°µ¿µµ Æ÷ÇÔÀÌ µÈ´Ù. ¼¼Æ÷¸Å°³¸é¿ªÀ̶õ ƯÀÌÇÑ ¹°ÁúÀ» °¨ÁöÇÒ ¼ö ÀÖ´Â ¼¼Æ÷¸¦ »ý¼ºÇÏ°Ô ÇÏ¿© ±×°ÍÀ¸·Î ÇÏ¿©±Ý ±× ¹°ÁúÀ» Æ÷½ÄÇÏ°Ô ÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | nerve cell | ÇÑ±Û | ½Å°æ¼¼Æ÷ |
|---|---|---|---|
| ¼³¸í | ½Å°æ¼¼Æ÷´Â ¿Ã¹Ù¸¥ ½Å°æÀü´ÞÀ» À§ÇÑ °¢ ºÎºÐº°·Î ³ª´µ¾îÁ® ÀÖ´Ù. ½Å°æ¼¼Æ÷¿¡¼´Â ÀüÇØÁ®¿À´Â ÀÚ±ØÀ» Àü±âÀûÀÎ ½ÅÈ£·Î ¹Ù²î¾î º¸³»°Å³ª ¹Þ°Ô µÈ´Ù. ÀÌ·± Àü±âÀûÀÎ Çö»óÀº °¢ ½Å°æ¼¼Æ÷³»¿¡ Á¸ÀçÇÏ´Â °¢ ÀÌ¿Âä³Î(ion channel: ionÀ̶õ ³ªÆ®·ý, Ä®·ý µîÀ» ÁöĪÇÏ´Â ¸»µé·Î½á, À̵éÀÌ ¼¼Æ÷¸·¿¡ ÀÇÇØ ³ª´µ¾îÁú ¶§ »ý±â´Â Àü¾ÐÂ÷°¡ Àü±âÀû ÀÚ±ØÀ» ÀÏÀ¸Å°°í À¯ÁöÇϴµ¥ °áÁ¤ÀûÀÎ ¿ªÇÒÀ» ÇÑ´Ù)µéÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ÀÌ·ç¾îÁö°Ô µÈ´Ù. |
||
| CCL | carcinoma cell line; certified cell line; Charcot-Leyden crystal; continuing care level; critical ca... |
|---|---|
| LCC | lactose coliform count; left circumflex coronary (artery); left common carotid; left coronary cusp; ... |
| MCT | manual cervical traction; mean cell thickness; mean cell threshold; mean circulation time; mean corp... |
| sq | cell ca squamous cell carcinoma |
| TCC | terminal complement complex; thromboplastic cell component; transitional-cell carcinoma; trichloroca... |
| fibrolamellar liver cell carcinoma | <tumour> Primary hepatic carcinoma in which malignant hepatocytes are intersected by fibrous lamellated bands. Synonym: oncocytic hepatocellular tumour. (05 Mar 2000) |
|---|---|
| large cell carcinoma | A group of lung cancers in which the cells are large and look abnormal. (12 Dec 1998) |
| liver cell carcinoma | <tumour> A carcinoma derived from parenchymal cells of the liver. Synonym: hepatocarcinoma, hepatocellular carcinoma, liver cell carcinoma. (05 Mar 2000) |
| T-cell-rich, B-cell lymphoma | <tumour> A B-cell lymphoma in which more than 90% of the cells are of T-cell origin, masking the large cells that form the neoplastic B-cell component. See: adult T-cell lymphoma. (05 Mar 2000) |
| acute renal failure | <nephrology> A sudden decline in renal function may be triggered by a number of acute disease processes. Examples include sepsis (infection), shock, trauma, kidney stones, kidney infection, drug toxicity (aspirin or lithium), poisons or toxins (drug abuse) or after injection with an iodinated contrast dye (adverse effect). Chronic renal failure represents a slow decline in kidney function over time. Chronic renal failure may be caused by a number of disorders which include long-standing hypertension, diabetes, congestive heart failure, lupus or sickle cell anaemia. Both forms of renal failure result in a life-threatening metabolic derangement. (27 Sep 1997) |
| aminoaciduria, renal | Impairment of renal tubular transport of amino acids. (12 Dec 1998) |
| back-pressure renal atrophy | <radiology> Caliectasis without obstruction, due to repeated episodes of obstruction, gradual loss of renal pyramids (12 Dec 1998) |
| base of renal pyramid | The outer broad part of a renal pyramid that lies next to the cortex. Synonym: basis pyramidis renis. (05 Mar 2000) |
| branchio-oto-renal syndrome | <syndrome> An autosomal dominant disorder manifested by various combinations of preauricular pits, branchial fistulae or cysts, lacrimal duct stenosis, hearing loss, structural defects of the outer, middle, or inner ear, and renal dysplasia. Associated defects include asthenic habitus, long narrow facies, constricted palate, deep overbite, and myopia. Hearing loss may be due to mondini type cochlear defect and stapes fixation. (12 Dec 1998) |
| capsular branches of renal artery | <anatomy, artery> Branches arising from the renal artery outside of the kidney that are distributed to the renal capsule. Synonym: rami capsulares arteriae renalis. (05 Mar 2000) |
| captopril renal scan | <radiology> In a kidney with a lesion in the afferent arteriole (e.g. Atherosclerotic plaque), reflex constriction of the efferent arteriole occurs through angiotensin system thus maintaining renal perfusion. ACE inhibition prevents constriction of efferent arteriole. Therefore, perfusion is decreased to a kidney with afferent lesions and the renal scan to looks WORSE. Bottom line: renal scans appear WORSE with captopril administration if there is a lesion in the afferent arteriole. See: renal artery stenosis (12 Dec 1998) |
| renal | <anatomy> Pertaining to the kidney, nephric. (18 Nov 1997) |
| renal adenocarcinoma | <radiology> Hypernephroma, renal cell carcinoma, arises from proximal collecting tubule, 10% bilateral adenocarcinoma types: papillary, alveolar, onchocytoma vascularity, 85% hypervascular (require pre-op embolization), 10% hypovascular (usually papillary type), 5% avascular associated with: tuberous sclerosis, von Hippel-Lindau syndrome see also: staging (12 Dec 1998) |
| renal adenocarcinoma: staging | <radiology> Typical presentation: Haematuria . . . . . 70% Fever . . . . . . . 16% Pain . . . . . . . . 50% Polycythemia . . . . 3% Palpable mass . . . 20% Anatomic staging (TNM): T1 Small tumour, kidney not enlarged T2 Large tumour, contained within renal capsule T3 Extension into perinephric fat or renal vein T4 Invasion of adjacent organs (12 Dec 1998) |
| renal adenocarcinoma: vascularity | <radiology> 85% hypervascular (require pre-op embolization), 10% hypovascular (usually the papillary type), 5% avascular also: 10% are bilateral (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|